Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors

被引：46

作者：

Chen, Xuxing ^{[1
,2
]}

Huan, Xiajuan ^{[3
]}

Liu, Qiufeng ^{[2
,4
]}

Wang, Yuqin ^{[1
]}

He, Qian ^{[1
]}

Tan, Cun ^{[1
]}

Chen, Yi ^{[3
]}

Ding, Jian ^{[3
]}

Xu, Yechun ^{[4
]}

Miao, Zehong ^{[3
]}

Yang, Chunhao ^{[1
]}

机构：

[1] Chinese Acad Sci, Shanghai Inst Mat Med, Synthet Organ & Med Chem Lab, State Key Lab Drug Res, Shanghai 201203, Peoples R China

[2] Univ Chinese Acad Sci, 19A Yuquan Rd, Beijing 100049, Peoples R China

[3] Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, State Key Lab Drug Res, Shanghai 201203, Peoples R China

[4] Chinese Acad Sci, Shanghai Inst Mat Med, Drug Discovery & Design Ctr, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2018年 / 145卷

基金：

中国国家自然科学基金;

关键词：

PARP1/2; inhibitor; Benzimidazole; 4,5,6,7-Tetrahydrothienopyridine; Co-crystal structure; Isothermal Titration Calorimetry; CANCER-THERAPY; POLYMERASE INHIBITORS; BIOLOGICAL EVALUATION; ANTICANCER ACTIVITY; EXCISION-REPAIR; CELLS; TARGETS; CYTOTOXICITY; ACTIVATION; BINDING;

D O I：

10.1016/j.ejmech.2018.01.018

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The nuclear protein poly(ADP-ribose) polymerases-1/2 (PARP-1/2) are involved in DNA repair damaged by endogenous or exogenous process. And PARP-1/2 inhibitors have been proved to be clinically efficacious for DNA repair deficient tumors in the past decade. We have developed a series of 4,5,6,7-tetrahydrothienopyridin-2-yl benzimidazole carboxamides as novel and potent PARP-1/2 inhibitors. The best compound resulted from this series is compound 27 which displays excellent PARP-1 and PARP-2 inhibitory activity with IC50 of 18 nM and 42 nM, respectively. Furthermore, it can selectively kill BRCA2 deficient V-C8 cells with a CC50 of 920 nM. In the MDA-MB-436 (BRCA-1 mutant) xenograft model, this compound was well tolerated and showed single-agent activity. Based on the results above, compound 27 has been selected as a lead candidate targeting PARP-1/2 and its preclinical characterization is also underway. (C) 2018 Elsevier Masson SAS. All rights reserved.

引用

页码：389 / 403

页数：15

共 39 条

[21] Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination [J].

Jones, Philip ;

Wilcoxen, Keith ;

Rowley, Michael ;

Toniatti, Carlo .

JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (08) :3302-3314

[22] Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation [J].

Kraus, W. Lee .

CURRENT OPINION IN CELL BIOLOGY, 2008, 20 (03) :294-302

[23] The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets [J].

Krishnakumar, Raga ;

Kraus, W. Lee .

MOLECULAR CELL, 2010, 39 (01) :8-24

[24] On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1 [J].

Luo, Xin ;

Kraus, W. Lee .

GENES & DEVELOPMENT, 2012, 26 (05) :417-432

[25] 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1 [J].

Menear, Keith A. ;

Adcock, Claire ;

Boulter, Robert ;

Cockcroft, Xiao-ling ;

Copsey, Louise ;

Cranston, Aaron ;

Dillon, Krystyna J. ;

Drzewiecki, Jan ;

Garman, Sheila ;

Gomez, Sylvie ;

Javaid, Hashim ;

Kerrigan, Frank ;

Knights, Charlotte ;

Lau, Alan ;

Loh, Vincent M., Jr. ;

Matthews, Ian T. W. ;

Moore, Stephen ;

O'Connor, Mark J. ;

Smith, Graeme C. M. ;

Martin, Niall M. B. .

JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (20) :6581-6591

[26]

Penning TD, 2010, CURR OPIN DRUG DISC, V13, P577

[27] Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer [J].

Penning, Thomas D. ;

Zhu, Gui-Dong ;

Gandhi, Viraj B. ;

Gong, Jianchun ;

Liu, Xuesong ;

Shi, Yan ;

Klinghofer, Vered ;

Johnson, Eric F. ;

Donawho, Cherrie K. ;

Frost, David J. ;

Bontcheva-Diaz, Velitchka ;

Bouska, Jennifer J. ;

Osterling, Donald J. ;

Olson, Amanda M. ;

Marsh, Kerman C. ;

Luo, Yan ;

Giranda, Vincent L. .

JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (02) :514-523

[28] A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation [J].

Plummer, Ruth ;

Lorigan, Paul ;

Steven, Neil ;

Scott, Lucy ;

Middleton, Mark R. ;

Wilson, Richard H. ;

Mulligan, Evan ;

Curtin, Nicola ;

Wang, Diane ;

Dewji, Raz ;

Abbattista, Antonello ;

Gallo, Jorge ;

Calvert, Hilary .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (05) :1191-1199

[29] Synthesis, Biological Evaluation, and Structure-Activity Relationships of a Novel Class of Apurinic/Apyrimidinic Endonuclease 1 Inhibitors [J].

Rai, Ganesha ;

Vyjayanti, Vaddadi N. ;

Dorjsuren, Dorjbal ;

Simeonov, Anton ;

Jadhav, Ajit ;

Wilson, David M., III ;

Maloney, David J. .

JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (07) :3101-3112

[30] Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors [J].

Skalitzky, DJ ;

Marakovits, JT ;

Maegley, KA ;

Ekker, A ;

Yu, XH ;

Hostomsky, Z ;

Webber, SE ;

Eastman, BW ;

Almassy, R ;

Li, JK ;

Curtin, NJ ;

Newell, DR ;

Calvert, AH ;

Griffin, RJ ;

Golding, BT .

JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (02) :210-213

← 1 2 3 4 →